PuSH - Publikationsserver des Helmholtz Zentrums München

Gutermuth, J.* ; Schmidt-Weber, C.B. ; Blank, S.

Supporting allergen-specific immunotherapy by inhibition of Janus kinases.

Allergy 74, 1814-1816 (2019)
Postprint DOI PMC
Open Access Green
Allergen-specific immunotherapy (AIT) is the only disease-modifying and curative treatment for allergic diseases. While in selected indications such as Hymenoptera venom allergy the curative success of AIT is impressingly high, in other disease manifestations it only reduces the symptoms to a certain extend in a fraction of patients. Key problems leading to a reduced efficacy of AIT seem to partly depend on local inflammatory processes that are not only causing side-effects, but additionally feed-back on the specific immune response. Thus, these inflammatory processes also influence the immunologic memory and impair the induction of immune tolerance (1). During the initial phase of AIT, a further increase of Th2 inflammation, including higher levels of allergen-specific IgE has been observed frequently and can be a reason for side-effects and even anaphylactic reactions during AIT.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Sonstiges: Meinungsartikel
Korrespondenzautor
ISSN (print) / ISBN 0105-4538
e-ISSN 1398-9995
Zeitschrift Allergy
Quellenangaben Band: 74, Heft: 9, Seiten: 1814-1816 Artikelnummer: , Supplement: ,
Verlag Wiley
Verlagsort 111 River St, Hoboken 07030-5774, Nj Usa
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed
Institut(e) Institute for Allergy Research (IAF)